BCA
CRSP icon

Berman Capital Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Berman Capital Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$11K Buy
+100
New +$12.6K ﹤0.01% 1149
2019
Q3 		– Sell
-200
Closed -$9K – 1464
2019
Q2 		$9K Buy
+200
New +$7.99K ﹤0.01% 761

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Berman Capital Advisors's CRSP Position: Q3 2021 in Review

Berman Capital Advisors opened a new position in CRISPR Therapeutics (CRSP) in Q3 2021: 100 shares worth $11K. The stake represents ﹤0.01% of the portfolio and ranks #1149 among its holdings. This is a return to the name: Berman Capital Advisors previously reported a position in CRSP as recently as Q2 2019.

Berman Capital Advisors first reported a position in CRSP in Q2 2019 and has held it in 2 quarters since. 473 funds tracked by Wall St. Rank hold CRSP as of Q3 2021.

  • Berman Capital Advisors held 100 shares of CRISPR Therapeutics worth $11K as of Q3 2021.
  • CRISPR Therapeutics was a new Berman Capital Advisors position in Q3 2021.
  • CRISPR Therapeutics made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1149 holding.
  • Berman Capital Advisors first reported a position in CRISPR Therapeutics in Q2 2019 and has held it in 2 quarters since.
  • 473 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.